Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score

Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score

IntroductionProgression of fibrotic interstitial lung disease (ILD) leads to irreversible loss of lung function and increased mortality. Based on an institutional ILD registry, we aimed to evaluate biomarkers derived from baseline patient characteristics, computed tomography (CT), and peripheral blo...

Full description

Bibliographic Details
Main Authors: Guangyu Shao, Patricia Hawle, Kaveh Akbari, Andreas Horner, Rainer Hintenberger, Bernhard Kaiser, Bernd Lamprecht, David Lang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Medicine
Subjects:
traction bronchiectasis
honeycombing
monocyte count
forced vital capacity (FVC)
diffusion capacity (DL)
idiopathic pulmonary fibrosis
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1043720/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1043720/full

Similar Items